|
(Health-NewsWire.Net, August 26, 2021 ) According to research report the In Vitro Diagnostics Quality Control Market is projected to reach $1,158 million by 2025 from $961 million in 2020, at a CAGR of 3.8% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582
Key players are focusing on increasing their presence in this growing market through both organic as well as inorganic growth strategies, such as product launches, agreements, partnerships, collaborations, and expansions. Due to the intense competition in this market, various market players are increasingly focusing on expanding their geographic presence in high-growth emerging markets.
Bio-Rad Laboratories Inc. (US) was the leading player in the IVD quality control market and accounted for the largest share in 2018. The company is a leading provider of clinical diagnostic systems, analytical devices, and instruments. The company has a robust portfolio of quality control products, data management solutions and quality assurance services for hospital laboratories, reference laboratories, transfusion laboratories, and physician office laboratories. Bio-Rad Laboratories’ position in the market can be attributed to its strong distribution network and its subsidiaries across the globe, which enables it to serve customers in North America, Europe, and the Asia Pacific.
To garner a large share of the IVD quality control market, the company continuously focuses on organic and inorganic growth strategies. For instance, in May 2019, the company launched InteliQ and Load-and-Go Tubes for quality controls to streamline the laboratory workflow. With this new launch the company enabled to strengthen its chemistry and immunoassay quality controls offerings.
Randox Laboratories Ltd. (UK) held the second-largest share of the global IVD quality control market. Its position in the market can be attributed to its robust product portfolio and a strong network of partners across the world. Under its flagship brands ‘Acusera’ and ‘RIQAS,’ the company offers various quality controls and EQA schemes across the globe. To maintain its position in the market, the company focuses on expanding its product portfolio through strategies, such as product launches and expansions. For instance, in August 2019, the company launched multi-analyte Acusera infectious disease (serology) control for the analysis of infectious diseases.
On the basis of type, the quality control products market is segmented into serum/plasma-based controls, whole blood-based controls, urine-based controls, and other controls (controls manufactured from spinal fluid, lipoprotein extracts, and immunoproteins).
Based on applications, the IVD quality control market is segmented into clinical chemistry, immunochemistry, hematology, coagulation & hemostasis, microbiology, molecular diagnostics, and other applications (ESR, urine chemistry, immunology, cardiac assessment, and blood morphology).
Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=198032582
The North America is expected to account for the largest share of the In Vitro Diagnostics Quality Control Market in 2020, followed by Europe. The large share of the North America can be attributed to the highly developed healthcare system in the US and Canada, and the presence of a large number of leading IVD quality control vendors & national clinical laboratories & hospitals in this region.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
